Expert: Trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity. Modulates mesolimbic and mesocortical dopaminergic circuits via indirect regulation of dopamine neuron firing, providing antipsychotic efficacy without D2 receptor blockade.

Everyday: Activates a recently discovered receptor (TAAR1) in the brain that modulates dopamine without directly blocking dopamine receptors — like adjusting the volume on a speaker indirectly through a remote control rather than covering the speaker itself.

Targets: []

Ulotaront - Schizophrenia - Ph3 - Relapse Prevention (DIAMOND 5) H2 2026

TAAR1/5-HT1A agonist. Novel non-D2 mechanism. Phase 3 DIAMOND 1&2 FAILED primary endpoints in schizophrenia (large placebo effect). DIAMOND 5 relapse prevention ongoing. Otsuka gained exclusive worldwide rights from Sumitomo Pharma Mar 2024.